BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saini A, Patel R, Gaba S, Singh G, Gupta GD, Monga V. Adenosine receptor antagonists: Recent advances and therapeutic perspective. Eur J Med Chem 2021;227:113907. [PMID: 34695776 DOI: 10.1016/j.ejmech.2021.113907] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Królicka E, Kieć-Kononowicz K, Łażewska D. Chalcones as Potential Ligands for the Treatment of Parkinson's Disease. Pharmaceuticals (Basel) 2022;15:847. [PMID: 35890146 DOI: 10.3390/ph15070847] [Reference Citation Analysis]
2 Park S, Ahn Y, Kim Y, Roh EJ, Lee Y, Han C, Yoo HM, Yu J. Design, Synthesis and Biological Evaluation of 1,3,5-Triazine Derivatives Targeting hA1 and hA3 Adenosine Receptor. Molecules 2022;27:4016. [DOI: 10.3390/molecules27134016] [Reference Citation Analysis]
3 Li Z, Kou L, Fu X, Xie Z, Xu M, Guo L, Lin T, Gong S, Zhang S, Liu M. Design, synthesis, and biological evaluation of triazole-pyrimidine-methylbenzonitrile derivatives as dual A2A/A2B adenosine receptor antagonists. J Enzyme Inhib Med Chem 2022;37:1514-26. [PMID: 35616298 DOI: 10.1080/14756366.2022.2077731] [Reference Citation Analysis]
4 Mori A, Chen JF, Uchida S, Durlach C, King SM, Jenner P. The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease. Molecules 2022;27:2366. [PMID: 35408767 DOI: 10.3390/molecules27072366] [Reference Citation Analysis]